Clinical Guides
Molluscum Contagiosum
A source-grounded guide to recognising molluscum contagiosum, choosing observation rather than unnecessary destructive treatment, reducing transmission and avoiding missed immunocompromise, ocular or genital disease.
MedNext Academy | 13 min read
Molluscum Contagiosum
A source-grounded guide to recognising molluscum contagiosum, choosing observation rather than unnecessary destructive treatment, reducing transmission and avoiding missed immunocompromise, ocular or genital disease.
Summary
Molluscum contagiosum is a benign superficial poxvirus infection producing smooth, pearly, dome-shaped papules, often with a central umbilication. Lesions are usually 2–5 mm and may become red or itchy as they inflame or resolve. [CDC 2025, Clinical features, lines 31–36.] In an otherwise healthy child or adult, it is ordinarily self-limiting: CDC reports spontaneous disappearance commonly within 6–12 months, although lesions can persist much longer. [CDC 2025, lines 33–35.] That natural history is the central prescribing fact. Observation, explanation and skin-care advice are often safer than attempting to eradicate every lesion.
Do not squeeze, pick, shave across or self-treat lesions. CDC warns that scraping and scooping increases scarring risk in otherwise healthy people; cryotherapy, curettage and laser require a trained clinician and can cause pain, irritation and scarring. [CDC 2025, Treatment and recovery, lines 37–43.] A treatment decision should follow confirmation of the diagnosis, lesion site, eczema or secondary infection, distress, pregnancy potential, immune status and the balance of cosmetic benefit against harm.
Adult genital lesions need sexual-health assessment because adult infection may be sexually acquired and mimics must be considered. [CDC 2025, Key points, lines 23–29; CDC 2025 About, lines 94–97.] Extensive, giant, facial, periocular, persistent or recurrent lesions should prompt assessment for immune suppression and specialist referral. This guide does not authorise a home drug regimen. If a clinician prescribes a topical or procedural treatment, they must verify the current product information, pregnancy status, site suitability and local service protocol.
How Common Is It?
Molluscum occurs worldwide, most often in children but at any age. CDC notes it is more common in developing countries, but that observation is not an Indian prevalence estimate and should not be presented as one. [CDC 2025, Key points, lines 23–28.] Apparent frequency is influenced by child contact networks, eczema, crowded living, sexual exposure in adults, diagnosis by non-specialists and whether minor self-limited lesions ever reach a clinic.
The useful clinical distinction is not a population count but the pattern. A few typical lesions in a well child who is not distressed create a different care problem from widespread facial lesions in an immunocompromised adult, inflamed lesions with suspected bacterial infection, lesions at the eyelid margin, or genital lesions in an adult. CDC identifies eczema, weakened immunity and warm, humid, crowded living conditions as risk factors. [CDC 2025 About, Risk factors, lines 85–91.]
The condition should not be medicalised solely because lesions are visible. Families often seek destructive treatment due to school, swimming or social anxiety, yet CDC says children do not need exclusion from school or daycare; swimming can continue if there are no open lesions that could become infected. [CDC 2025 About, Prevention, lines 98–106.] A clinician should explain that normal activity is generally appropriate while practical measures reduce direct contact with lesions and sharing of personal items.
In Indian services, long waits for dermatology should not lead to unsafe over-the-counter acids or unregulated procedures. Most uncomplicated disease can be managed with confirmation, conservative skin care and safety-netting in primary care; referral capacity should be reserved for diagnostic uncertainty, sensitive sites, severe burden, immune suppression or complications.
Risk Factors
Transmission occurs by direct skin contact and through contaminated objects such as towels, clothing, toys or pool equipment. Autoinoculation follows scratching, touching, shaving or hair removal over lesions. [CDC 2025 About, How it spreads, lines 92–97.] Ask about eczema, dry or itchy skin, household contacts, shared towels, close-contact sport, swimming practices, genital distribution, sexual exposure and any attempt to remove lesions. The history should be matter-of-fact and non-stigmatising.
Impaired immunity changes both severity and urgency. CDC reports that immunosuppressed people may have more and larger lesions and often do not respond to traditional therapies. [CDC 2025, Clinical features and therapy for immunocompromised people, lines 33–36 and 61–66.] Ask about HIV status where clinically appropriate, cancer treatment, organ transplantation, systemic immunosuppressants and recurrent or unusual infections. Do not diagnose HIV from lesions alone; arrange proportionate testing and specialist assessment with consent.
Eczema is relevant because itch and scratching amplify autoinoculation and can disrupt the skin barrier. The accompanying dermatitis needs treatment on its own terms; it is not proof that every molluscum lesion requires removal. public health notes that a clinician may use steroid cream for itchy, dry or sore eczema-like skin around lesions, while antibiotics are for bacterial infection rather than the virus. [current guidelines (2026), Treating molluscum, lines 80–89.]
Pregnancy and lesion site are medication safeguards. CDC identifies podophyllotoxin 0.5% as a clinician-prescribed local therapy for non-pregnant women and advises against it in pregnancy because of potential fetal risk. [CDC 2025, Topical therapy, lines 53–58.] This does not make it a routine treatment, nor does it establish safety for self-purchase, genital mucosa or every patient. Verify diagnosis and product instructions before any prescription.
Diagnosis
Diagnosis is usually clinical, based on grouped, firm, smooth papules with a central dimple. The aim is to confirm a benign pattern while identifying lesions that may be mimics, complications or a clue to immune suppression. A photograph can help document progression, with consent and appropriate privacy safeguards.
History
Ask when lesions began, whether they itch, hurt, bleed, crust or discharge, whether they are spreading after scratching or shaving, and whether household or sexual contacts have similar lesions. Record eczema, topical products, prior procedures, pregnancy possibility and immune-suppressing conditions or treatment. Adult genital distribution needs a sexual-health history and consideration of other sexually transmitted infections. CDC notes that many adult infections are sexually acquired. [CDC 2025 About, lines 94–97.]
Examination
Inspect distribution, size, number, umbilication, inflammation, excoriation and evidence of bacterial infection. Examine cautiously around the eyelids, face and genital area; respect consent and use a chaperone where appropriate. Look for eczema, crusting, tenderness, purulence or atypical morphology. Extensive, coalescent, unusually large or facial disease increases concern for immune compromise, but is not diagnostic by itself. Public health guidance specifically notes that weakened immunity may be associated with facial/periocular, larger or numerous lesions. [current guidelines (2026), lines 42 and 74–79.]
Investigations
Typical uncomplicated lesions need no routine laboratory test. Investigate only when the diagnosis is uncertain, lesions are genital or atypical, infection is suspected, disease is severe or immune suppression is possible. The test should answer a defined question: for example, sexual-health testing after consent, bacterial culture for purulent secondary infection, or immune assessment where presentation and history justify it. Avoid biopsy or indiscriminate blood tests merely because lesions persist; persistence is compatible with the known natural course. [CDC 2025, lines 33–35.]
Differential Diagnosis
Consider viral warts, folliculitis, milia, epidermoid cysts, acneiform lesions, keratosis pilaris, varicella-like eruptions, scabies-associated papules and benign adnexal lesions. In the genital area, differential diagnosis includes anogenital warts, herpes simplex, syphilis and other papular dermatoses. The diagnosis must be revisited when lesions lack umbilication, ulcerate, become persistently painful, have an atypical distribution or do not fit the patient’s course.
Inflamed molluscum may look infected. Redness and swelling can occur during spontaneous evolution; purulent discharge, expanding erythema, heat, increasing pain, fever or crusting suggest secondary bacterial infection and require clinical review. CDC identifies bacterial infection after scratching or breaking lesions as the common complication. [CDC 2025 About, lines 82–84.] Do not prescribe systemic antibiotics for uncomplicated viral papules.
Eczema surrounding lesions is common and can be more symptomatic than the virus. Treating dry, itchy skin and limiting scratching may reduce autoinoculation; it is distinct from treating molluscum directly. [current guidelines (2026), lines 61–73 and 86–89.] In contrast, widespread refractory lesions in an immunosuppressed person should not be repeatedly frozen in primary care without review of immune status and specialist options.
A genital eruption deserves particular care because labelling it “molluscum” can delay diagnosis of another STI. Confirm visually where possible, offer appropriate sexual-health assessment and explain that sex partners need information on exposure risk without asserting blame. The patient’s symptoms, distribution, examination and local testing pathway decide the work-up.
Management
For typical, limited molluscum in an immunocompetent person, start with reassurance and observation. CDC states that lesions are benign and resolve without scarring if left alone, while otherwise healthy people should not have them removed by scraping or scooping because this increases scarring. [CDC 2025, lines 37–40.] Explain the expected time course, the possibility of new lesions from autoinoculation, and the fact that visible inflammation may occur before resolution.
Reduce spread without isolating the child. Keep lesions covered when practical, use waterproof covering for swimming, do not share towels, bedding or clothes, avoid squeezing and scratching, and avoid shaving or hair removal over lesions. [CDC 2025 About, lines 92–106; current guidelines (2026), lines 61–73.] Manage dry, itchy skin with bland emollient measures; refer to a clinician for eczema treatment if symptoms are significant.
Offer treatment only after a patient-centred discussion of site, burden, irritation, cosmetic impact, transmission concern, immune status and treatment harm. Physical removal is clinician-delivered and may cause pain, irritation or scarring. [CDC 2025, lines 41–43.] Topical options are clinician-prescribed; product choice must account for location, pregnancy and local availability. CDC says cantharidin must be applied in a clinician’s office, and that imiquimod is not recommended for children due to lack of demonstrated benefit and adverse events. [CDC 2025, lines 53–60.]
Treat secondary bacterial infection when clinically diagnosed, not pre-emptively. Escalate immunocompromised, periocular, genital, extensive or atypical disease. For immunocompromised people, CDC emphasises improving immune function as the most effective approach; this demands coordination with the treating specialty rather than a cosmetic procedure alone. [CDC 2025, lines 61–71.]
Prescribing Information
Most patients need no antiviral, antibiotic, destructive agent or dose calculation. The safest prescription may be none: observation plus written advice. That is an active choice supported by CDC’s statement that healthy people usually recover without treatment. [CDC 2025 About, lines 107–115.] Document diagnostic confidence, lesion site, eczema status, immune status, advice on transmission and the reason treatment is not indicated.
If secondary eczema is symptomatic, public health guidance describes steroid cream for itchy, dry or sore eczema-like skin around lesions; this is treatment of dermatitis, not a cure for molluscum. [current guidelines (2026), lines 80–89.] Select potency, site, duration, paediatric suitability and infection precautions from the current local formulary; do not apply an unverified schedule from this guide. If bacterial infection is suspected, assess before prescribing antibiotics.
If a clinician considers a lesion-directed treatment, check contraindications and harms first. CDC describes clinician-prescribed podophyllotoxin 0.5% for non-pregnant women and advises against its use in pregnancy owing to potential fetal risk; cantharidin is provider-applied; and imiquimod is not recommended in children because it lacks proven efficacy and may cause adverse events. [CDC 2025, lines 53–60.] These facts are not an endorsement for routine use, self-treatment or use on sensitive mucosa.
Cryotherapy, curettage and laser are procedures, not simple prescriptions. CDC notes they require trained care and can produce pain, irritation and scarring. [CDC 2025, lines 41–43.] Record consent, site, number of lesions, adverse-effect counselling and review plan. Immunocompromised disease requires specialist coordination; CDC notes traditional treatments often have limited response and immune restoration is central. [CDC 2025, lines 61–66.]
When to Refer
Refer or seek specialist advice for diagnostic uncertainty; lesions around the eye or eyelid; genital lesions; very numerous, giant, facial, persistent or functionally distressing lesions; significant eczema or suspected bacterial infection; and any suspected immune suppression. public health guidance identifies periocular/genital lesions, extensive disease and weakened immunity as reasons for specialist referral. [current guidelines (2026), lines 74–94.]
Urgent eye assessment is appropriate when lesions are close to the lid margin, ocular symptoms are present or the diagnosis is uncertain. Avoid home acids, picking or untrained cryotherapy near the eye. Sexual-health referral is appropriate for adult genital disease, where diagnosis, partner communication, pregnancy considerations and STI testing may need a confidential service.
Immunocompromised people require more than a dermatology procedure. Coordinate with HIV, oncology, transplant or rheumatology services to review immune status and current medicines. CDC describes more numerous or larger lesions, limited response to traditional treatments and the importance of therapies that improve immune function. [CDC 2025, lines 33–36 and 61–71.] Do not stop an immunosuppressant without the specialist who prescribed it.
For a child with typical lesions and no red flags, referral is usually unnecessary. A clear primary-care plan—emollient advice, avoidance of picking, covered lesions when needed, no shared towels, expected course and return precautions—prevents both overtreatment and neglect.
Red Flags
Arrange prompt review for lesions near the eye or genital area, diagnostic doubt, painful or rapidly inflamed lesions, purulence, spreading erythema, crusting, fever, extensive disease, marked distress, or disease in a person with HIV, cancer treatment, transplant or other immune suppression. [current guidelines (2026), lines 74–94.] Atypical, ulcerated, bleeding or rapidly growing lesions warrant reconsideration of the diagnosis rather than repeated molluscum treatment.
The immunocompromised patient is the key safety exception. More and larger lesions may occur, conventional treatments can fail, and secondary infection may be more serious. [CDC 2025, lines 33–36 and 61–71.] Escalate for coordinated immune assessment; do not infer cause, disclose status or alter specialist medicines without consent and expert input.
Medication red flags include pregnancy or pregnancy possibility before any lesion-directed medicine, use on facial/periocular/genital skin without specialist advice, and an internet product of uncertain contents. CDC specifically advises that podophyllotoxin is not recommended during pregnancy and that some treatments must be prescribed or applied by a clinician. [CDC 2025, lines 53–60.]
A practical red flag is a family attempting repeated home removal. It can spread lesions, cause scarring and introduce bacterial infection. CDC advises against self-removal, and public health advises against squeezing or scratching. [CDC 2025 About, lines 109–115; current guidelines (2026), lines 69–73.]
Indian Clinical Context
There is no single national Indian molluscum prescription that safely replaces examination, local dermatology access and product verification. In many settings, the highest-value intervention is preventing harm from unnecessary procedures or unregulated topical products. Explain that a self-limiting condition does not need expensive “viral clearance” packages, and give written return precautions in the patient’s preferred language.
Primary-care and school advice should reduce stigma. CDC says children with molluscum do not need exclusion from daycare or school, and covered lesions plus ordinary hand and item hygiene are practical prevention measures. [CDC 2025 About, lines 98–106.] Local school or swimming requirements may differ, but clinical advice should not exaggerate routine transmission risk.
For adult genital lesions, make confidential sexual-health assessment available where possible. For immune suppression, coordinate referral rather than treating lesions in isolation. Access to HIV testing, antiretroviral care, cancer services, transplantation follow-up and dermatology changes the safe pathway; do not label a patient or make assumptions based on lesion count alone.
Where procedural services are limited, avoid substituting poorly evidenced self-treatment. Treat eczema and secondary infection when clinically present, protect the skin barrier and arrange review for sensitive-site or extensive disease. This is resource-conscious care without lowering the threshold for serious differential diagnoses.
NMC Competency Mapping
This guide supports supervised learning across Dermatology, Microbiology, Paediatrics, Community Medicine, Pharmacology and AETCOM. The learner should recognise typical lesions, distinguish uncomplicated disease from referral patterns, explain autoinoculation and prevention, assess eczema and immune risk, and avoid harmful overprescribing. Exact NMC codes must be confirmed from the institution’s current curriculum ledger. [NMC, Competency Based Medical Education Curriculum, current undergraduate portal.]
In a case discussion, assess whether the student asks about duration, itch, scratching, shaving, lesion site, household contact, sexual exposure when appropriate, pregnancy possibility, immune suppression and prior topical use. The student should explain why observation can be an evidence-based management choice and why scraping is not a neutral intervention.
A prescribing station should test medication safety rather than recall. The learner must identify that routine antiviral or antibiotic therapy is not indicated, that dermatitis and bacterial infection are different problems, and that topical/procedural options require a current formulary, site-specific cautions and pregnancy review. They should refer periocular, genital, extensive and immunocompromised presentations.
Professional conduct includes non-stigmatising explanation, confidential sexual history, consent for examination or photography, safeguarding where indicated and clear written advice. The endpoint is safe outpatient care and timely escalation, not a promise of immediate cosmetic clearance.
Key Exam Pearls for NEET PG
Molluscum contagiosum is a poxvirus infection with small pearly umbilicated papules. It is usually benign and self-limiting; lesions commonly resolve in 6–12 months but may persist longer. [CDC 2025, lines 23–35.] The exam trap is assuming that every lesion needs destruction.
Know the transmission principles: direct contact, shared objects and autoinoculation from scratching or shaving. Cover lesions when practical, avoid shared towels and do not squeeze lesions. [CDC 2025 About, lines 92–115.] School exclusion is generally unnecessary for children with uncomplicated disease.
For treatment, distinguish observation from a treatment failure. CDC advises against scraping and scooping in otherwise healthy people because of scarring. Cryotherapy, curettage and laser can cause pain, irritation and scarring and require trained care. [CDC 2025, lines 37–43.] Imiquimod is not recommended in children because efficacy is unproven and adverse events occur. [CDC 2025, lines 53–60.]
Red-flag patterns are periocular or genital lesions, extensive/atypical disease and immune suppression. Immunocompromised people may have more and larger lesions and need coordinated assessment. [CDC 2025, lines 61–71; current guidelines (2026), lines 74–94.]
Frequently Asked Questions
Do all molluscum lesions need to be frozen or removed?
No. In otherwise healthy people, lesions commonly resolve without treatment. Scraping or scooping can scar, and clinician procedures can cause pain, irritation and scarring. Observation with skin-care and transmission advice is often the safest option. [CDC 2025, lines 37–43 and 107–115.]
When should molluscum contagiosum be assessed urgently?
Prompt assessment is appropriate for lesions near the eye or genitals, marked pain, pus, spreading redness, diagnostic uncertainty, extensive disease or possible immune suppression. These situations may need specialist or sexual-health input rather than repeated home treatment. [current guidelines (2026), lines 74–94.]
Can a child attend school or swim with molluscum contagiosum?
CDC says exclusion from school or daycare is not needed. Swimming can continue when there are no open lesions that could become infected; covering lesions and not sharing towels or clothing reduces spread. Follow local facility rules if they differ. [CDC 2025 About, lines 98–106.]
Why are widespread lesions more concerning in an immunocompromised person?
Immune suppression can be associated with more and larger lesions, poor response to conventional treatment and more serious secondary infection. The response is coordinated review of immune status and specialist care, not unsupervised escalation of destructive treatment. [CDC 2025, lines 61–71.]
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic